PH12016501519B1 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions - Google Patents
Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositionsInfo
- Publication number
- PH12016501519B1 PH12016501519B1 PH12016501519A PH12016501519A PH12016501519B1 PH 12016501519 B1 PH12016501519 B1 PH 12016501519B1 PH 12016501519 A PH12016501519 A PH 12016501519A PH 12016501519 A PH12016501519 A PH 12016501519A PH 12016501519 B1 PH12016501519 B1 PH 12016501519B1
- Authority
- PH
- Philippines
- Prior art keywords
- compositions
- solid pharmaceutical
- pharmaceutical compositions
- biopterin derivatives
- biopterin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14162727.3A EP2926805B1 (en) | 2014-03-31 | 2014-03-31 | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
| PCT/EP2015/056824 WO2015150294A1 (en) | 2014-03-31 | 2015-03-30 | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016501519A1 PH12016501519A1 (en) | 2017-02-06 |
| PH12016501519B1 true PH12016501519B1 (en) | 2017-02-06 |
Family
ID=50389975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016501519A PH12016501519B1 (en) | 2014-03-31 | 2016-08-01 | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US9895372B2 (enExample) |
| EP (2) | EP2926805B1 (enExample) |
| JP (3) | JP6552515B2 (enExample) |
| KR (1) | KR102374500B1 (enExample) |
| CN (2) | CN113521017A (enExample) |
| AU (2) | AU2015239736B2 (enExample) |
| CA (1) | CA2938267C (enExample) |
| CL (1) | CL2016002463A1 (enExample) |
| CY (1) | CY1117881T1 (enExample) |
| DK (1) | DK2926805T3 (enExample) |
| ES (1) | ES2586945T3 (enExample) |
| HR (1) | HRP20160802T1 (enExample) |
| HU (1) | HUE030221T2 (enExample) |
| IL (1) | IL248090B (enExample) |
| MX (1) | MX377919B (enExample) |
| MY (1) | MY180844A (enExample) |
| PE (1) | PE20161253A1 (enExample) |
| PH (1) | PH12016501519B1 (enExample) |
| PL (1) | PL2926805T3 (enExample) |
| PT (1) | PT2926805T (enExample) |
| RS (1) | RS54973B1 (enExample) |
| RU (1) | RU2694368C2 (enExample) |
| SA (1) | SA516371933B1 (enExample) |
| SG (1) | SG11201606151SA (enExample) |
| SI (1) | SI2926805T1 (enExample) |
| SM (1) | SMT201600246B (enExample) |
| WO (1) | WO2015150294A1 (enExample) |
| ZA (1) | ZA201605271B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4309653A1 (en) | 2014-02-07 | 2024-01-24 | Exithera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| PL2926805T3 (pl) * | 2014-03-31 | 2016-12-30 | Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji | |
| JP2016168783A (ja) * | 2015-03-13 | 2016-09-23 | 株式会社東芝 | 記録装置、記録方法、及び記録媒体 |
| US12171766B2 (en) | 2021-12-03 | 2024-12-24 | Verinos Operations Gmbh | Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury |
| CN111491635A (zh) * | 2017-09-01 | 2020-08-04 | 显莎制药公司 | 包含墨蝶呤的药物组合物及其用途 |
| JP6565103B2 (ja) * | 2017-09-06 | 2019-08-28 | 株式会社昭和冷凍プラント | 香気成分含有水溶液を含む液状製品の製造方法 |
| ES3041002T3 (en) * | 2019-09-25 | 2025-11-06 | Ptc Therapeutics Mp Inc | Methods for treating hyperphenylalaninemia |
| CA3235704A1 (en) | 2021-12-03 | 2023-06-08 | Verinos Operations Gmbh | Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury |
| EP4539850A1 (en) | 2022-05-06 | 2025-04-23 | VeriNOS operations GmbH | Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922713A (en) * | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
| ATE201412T1 (de) | 1997-10-06 | 2001-06-15 | Ernst Werner | Pteridinderivate als no synthase-hemmer |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
| CN1894251B (zh) * | 2003-11-17 | 2011-06-29 | 默克和西伊公司 | (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型 |
| EP1757293B1 (en) * | 2004-05-11 | 2012-10-10 | Daiichi Sankyo Company, Limited | Bh4-responsive hyperphenylalaninemia remedies |
| SE0401826D0 (sv) | 2004-07-09 | 2004-07-09 | Trimble Ab | Method of preparing a winding for an n-phase motor |
| CN101132776A (zh) * | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| EP1669355A1 (en) * | 2004-12-02 | 2006-06-14 | Vasopharm Biotech GmbH | Aminotetrahydropteridines and processes for manufacture thereof |
| ES2906582T3 (es) * | 2007-04-11 | 2022-04-19 | Biomarin Pharm Inc | Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida |
| US8222828B2 (en) | 2007-04-24 | 2012-07-17 | Osram Ag | Circuit arrangement for igniting and operating a discharge lamp |
| US20110144117A1 (en) | 2008-08-12 | 2011-06-16 | Orpha Swiss Gmbh | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin |
| CN103458900A (zh) * | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| EP2750664A1 (en) * | 2011-08-30 | 2014-07-09 | Fresenius Kabi USA, LLC | Levothyroxine formulations |
| PL2926805T3 (pl) * | 2014-03-31 | 2016-12-30 | Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji |
-
2014
- 2014-03-31 PL PL14162727.3T patent/PL2926805T3/pl unknown
- 2014-03-31 SI SI201430042A patent/SI2926805T1/sl unknown
- 2014-03-31 DK DK14162727.3T patent/DK2926805T3/en active
- 2014-03-31 RS RS20160595A patent/RS54973B1/sr unknown
- 2014-03-31 EP EP14162727.3A patent/EP2926805B1/en active Active
- 2014-03-31 PT PT141627273T patent/PT2926805T/pt unknown
- 2014-03-31 HU HUE14162727A patent/HUE030221T2/en unknown
- 2014-03-31 ES ES14162727.3T patent/ES2586945T3/es active Active
-
2015
- 2015-03-30 SG SG11201606151SA patent/SG11201606151SA/en unknown
- 2015-03-30 AU AU2015239736A patent/AU2015239736B2/en active Active
- 2015-03-30 EP EP15715697.7A patent/EP3125864A1/en not_active Withdrawn
- 2015-03-30 CN CN202110640860.1A patent/CN113521017A/zh active Pending
- 2015-03-30 PE PE2016001818A patent/PE20161253A1/es unknown
- 2015-03-30 MX MX2016012784A patent/MX377919B/es unknown
- 2015-03-30 CA CA2938267A patent/CA2938267C/en active Active
- 2015-03-30 KR KR1020167025896A patent/KR102374500B1/ko active Active
- 2015-03-30 RU RU2016141449A patent/RU2694368C2/ru active
- 2015-03-30 WO PCT/EP2015/056824 patent/WO2015150294A1/en not_active Ceased
- 2015-03-30 CN CN201580017915.6A patent/CN106572976A/zh active Pending
- 2015-03-30 MY MYPI2016702995A patent/MY180844A/en unknown
- 2015-03-30 JP JP2016556270A patent/JP6552515B2/ja active Active
- 2015-03-30 US US14/913,665 patent/US9895372B2/en active Active
-
2016
- 2016-07-06 HR HRP20160802TT patent/HRP20160802T1/hr unknown
- 2016-07-26 SM SM201600246T patent/SMT201600246B/it unknown
- 2016-07-29 ZA ZA2016/05271A patent/ZA201605271B/en unknown
- 2016-08-01 PH PH12016501519A patent/PH12016501519B1/en unknown
- 2016-08-04 CY CY20161100768T patent/CY1117881T1/el unknown
- 2016-09-27 IL IL24809016A patent/IL248090B/en active IP Right Grant
- 2016-09-27 SA SA516371933A patent/SA516371933B1/ar unknown
- 2016-09-29 CL CL2016002463A patent/CL2016002463A1/es unknown
-
2017
- 2017-05-02 US US15/584,890 patent/US10016431B2/en active Active
-
2018
- 2018-06-08 US US16/003,374 patent/US10493075B2/en active Active
-
2019
- 2019-07-02 JP JP2019123306A patent/JP6879582B2/ja active Active
- 2019-10-21 US US16/659,401 patent/US10925877B2/en active Active
-
2020
- 2020-06-12 AU AU2020203880A patent/AU2020203880B2/en active Active
-
2021
- 2021-01-20 US US17/153,749 patent/US11717522B2/en active Active
- 2021-04-22 JP JP2021072278A patent/JP7178731B2/ja active Active
-
2023
- 2023-07-20 US US18/224,515 patent/US12458644B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MD20170070A2 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| MX386256B (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| PH12019500024A1 (en) | Pharmaceutical compositions | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| EA201990834A1 (ru) | Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний |